A Test in Context: Hemoglobin A1c and Cardiovascular Disease

M. Odette Gore, Darren K. McGuire

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Measurement of glycated hemoglobin (HbA1c), the most widely accepted indicator of long-term glycemic exposure, is central for the diagnosis and management of diabetes mellitus. Levels of HbA1c track epidemiologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, results in decreased risk of microvascular complications, including diabetic kidney disease, neuropathy, and retinopathy. The relationship between HbA1c reduction and cardiovascular disease prevention in patients with diabetes is more complex, with data from large randomized trials published over the past decade providing clear evidence that lowering of HbA1c per se is an inadequate marker for a therapeutic regimen's impact on cardiovascular outcomes and patient survival. Recent revisions in professional society guidelines moved away from uniform recommendations and toward a more nuanced, patient-centered approach to HbA1c therapeutic targets. The context and key evidence underpinning these recent changes are discussed in this paper, alongside a brief overview of HbA1c contemporary assays and their limitations.

Original languageEnglish (US)
Pages (from-to)2479-2486
Number of pages8
JournalJournal of the American College of Cardiology
Volume68
Issue number22
DOIs
StatePublished - Dec 6 2016

Fingerprint

Hemoglobins
Cardiovascular Diseases
Glycosylated Hemoglobin A
Diabetic Nephropathies
Diabetes Complications
Diabetes Mellitus
Guidelines
Survival
Therapeutics

Keywords

  • diabetes mellitus
  • macrovascular complications
  • prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A Test in Context : Hemoglobin A1c and Cardiovascular Disease. / Gore, M. Odette; McGuire, Darren K.

In: Journal of the American College of Cardiology, Vol. 68, No. 22, 06.12.2016, p. 2479-2486.

Research output: Contribution to journalReview article

@article{760de166fbf3452182b1733d1a975485,
title = "A Test in Context: Hemoglobin A1c and Cardiovascular Disease",
abstract = "Measurement of glycated hemoglobin (HbA1c), the most widely accepted indicator of long-term glycemic exposure, is central for the diagnosis and management of diabetes mellitus. Levels of HbA1c track epidemiologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, results in decreased risk of microvascular complications, including diabetic kidney disease, neuropathy, and retinopathy. The relationship between HbA1c reduction and cardiovascular disease prevention in patients with diabetes is more complex, with data from large randomized trials published over the past decade providing clear evidence that lowering of HbA1c per se is an inadequate marker for a therapeutic regimen's impact on cardiovascular outcomes and patient survival. Recent revisions in professional society guidelines moved away from uniform recommendations and toward a more nuanced, patient-centered approach to HbA1c therapeutic targets. The context and key evidence underpinning these recent changes are discussed in this paper, alongside a brief overview of HbA1c contemporary assays and their limitations.",
keywords = "diabetes mellitus, macrovascular complications, prevention",
author = "Gore, {M. Odette} and McGuire, {Darren K.}",
year = "2016",
month = "12",
day = "6",
doi = "10.1016/j.jacc.2016.08.070",
language = "English (US)",
volume = "68",
pages = "2479--2486",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "22",

}

TY - JOUR

T1 - A Test in Context

T2 - Hemoglobin A1c and Cardiovascular Disease

AU - Gore, M. Odette

AU - McGuire, Darren K.

PY - 2016/12/6

Y1 - 2016/12/6

N2 - Measurement of glycated hemoglobin (HbA1c), the most widely accepted indicator of long-term glycemic exposure, is central for the diagnosis and management of diabetes mellitus. Levels of HbA1c track epidemiologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, results in decreased risk of microvascular complications, including diabetic kidney disease, neuropathy, and retinopathy. The relationship between HbA1c reduction and cardiovascular disease prevention in patients with diabetes is more complex, with data from large randomized trials published over the past decade providing clear evidence that lowering of HbA1c per se is an inadequate marker for a therapeutic regimen's impact on cardiovascular outcomes and patient survival. Recent revisions in professional society guidelines moved away from uniform recommendations and toward a more nuanced, patient-centered approach to HbA1c therapeutic targets. The context and key evidence underpinning these recent changes are discussed in this paper, alongside a brief overview of HbA1c contemporary assays and their limitations.

AB - Measurement of glycated hemoglobin (HbA1c), the most widely accepted indicator of long-term glycemic exposure, is central for the diagnosis and management of diabetes mellitus. Levels of HbA1c track epidemiologically with diabetic complications, and glycemic control, as reflected by HbA1c reduction, results in decreased risk of microvascular complications, including diabetic kidney disease, neuropathy, and retinopathy. The relationship between HbA1c reduction and cardiovascular disease prevention in patients with diabetes is more complex, with data from large randomized trials published over the past decade providing clear evidence that lowering of HbA1c per se is an inadequate marker for a therapeutic regimen's impact on cardiovascular outcomes and patient survival. Recent revisions in professional society guidelines moved away from uniform recommendations and toward a more nuanced, patient-centered approach to HbA1c therapeutic targets. The context and key evidence underpinning these recent changes are discussed in this paper, alongside a brief overview of HbA1c contemporary assays and their limitations.

KW - diabetes mellitus

KW - macrovascular complications

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=84999885289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999885289&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.08.070

DO - 10.1016/j.jacc.2016.08.070

M3 - Review article

C2 - 27908354

AN - SCOPUS:84999885289

VL - 68

SP - 2479

EP - 2486

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 22

ER -